Purpose: To evaluate an interleaved MRI sampling strategy that acquires both high temporal resolution (HTR) dynamic contrast-enhanced (DCE) data for quantifying breast tumor blood flow (TBF) and high spatial resolution (HSR) DCE data for clinical reporting, following a single standard injection of contrast agent. Methods: A simulation study was used to evaluate the performance of the interleaved technique under different conditions. In a prospective clinical study, 18 patients with primary breast cancer, who were due to undergo neoadjuvant chemotherapy (NACT), were examined using interleaved HTR and HSR DCE-MRI at 1.5 Tesla. Tumor regions of interest were analyzed with a two-compartment tracer kinetic model. Paired parameters (n ¼ 10) from the data acquired before and post-cycle 2 of NACT were compared using the nonparametric Wilcoxon signed-rank test. Results: Simulations demonstrated that TBF was reliably estimated using the proposed strategy. The region of interest analysis revealed significant changes in TBF (0.81-0.43 mL/min/mL; P ¼ 0.002) following two cycles of NACT. The HSR data were reported in the normal way and enabled the assessment of tumor volume, which decreased by 53% following NACT (P ¼ 0.065). Conclusions: TBF can be measured reliably using the proposed strategy without compromising a standard clinical protocol. Furthermore, in our feasibility study, TBF decreased significantly following NACT, whereas capillary permeability surface-area product did not. Magn Reson Med 79:317-326, 2018. V C 2017 International Society for Magnetic Resonance in Medicine.
INTRODUCTION
Breast cancer is the most common cancer in women worldwide. Survival rates for women who are diagnosed early have improved, but this is not the case with late stage disease (1) . Patients with advanced breast cancer often undergo neoadjuvant chemotherapy (NACT), with the aim of reducing tumor size. Nevertheless, a significant proportion of patients do not benefit from the treatment (2), but still suffer from its side effects (3, 4) . It is important to identify these patients at an early stage of treatment and, where possible, change their therapy.
Treatment response is currently assessed by a combination of clinical examination and imaging techniques such as mammography, ultrasound, and MRI. However, these techniques are typically limited to evaluating morphological changes, such as tumor diameter (5) and volume (6) . It is recognized that changes in physiology, such as tumor blood flow (TBF), precede morphological changes, and this allows an assessment of treatment response at an earlier stage of therapy (7, 8) . Since 1990 , several studies have demonstrated that it is possible to estimate physiological processes using dynamic contrast-enhanced (DCE) MRI, and many studies have exploited this approach to monitor NACT response, either by semi-quantitative signal-time curve characterization or by measurement and modeling of tumor contrast uptake (9) (10) (11) (12) (13) .
Despite the promise of DCE-MRI to monitor treatment response, there has been limited adoption of quantitative MRI techniques into clinical practice. Accurate modeling of tracer kinetic time series requires the use of imaging protocols with high temporal resolution (HTR), and such data are usually acquired at the expense of high spatial resolution (HSR) (14) . The American College of Radiology guidelines recommend the acquisition of HSR data: a slice thickness of less than 3 mm with in-plane spatial resolution of 1 mm (or less), suggesting that a temporal resolution of less than 4 min will suffice for "accurate capture of lesion kinetics" (http://www.acr.org/QualitySafety/Standards-Guidelines). In the case of TBF measurement, however, the sampling interval plays a major role with the necessity of acquiring data in both the breasts and a feeding artery (15) (16) (17) . A sampling rate of one imaging volume every 2 or 3 s is needed to capture the temporal characteristics of the arterial input function (AIF) during the early passes of the contrast agent bolus, although this sampling rate can be relaxed later in the time course (16, 17) .
Some studies simply neglect HSR images or breast coverage to improve the sampling rate (14, 18, 19) , whereas others have proposed different approaches to meet these conflicting requirements. A two-bolus technique was proposed to allow for separate HSR and HTR imaging; however, it significantly increases scanning time and reduces the contrast dose that can be used in each bolus (20) . Song et al demonstrated a technique that allows acquisition of HTR images (12-15 s) while simultaneously allowing the reconstruction of HSR images from the same data sets (21). Saranathan et al proposed an acquisition technique that switched between HTR with moderate spatial resolution (9 s; 1.1 Â 2.5 Â 4 mm) during the contrast agent wash-in phase and low temporal resolution, but HSR (120 s; 1.1 Â 1 Â 1.2 mm) during the washout phase (22) . Despite these proposals, acquisition rates for estimation of TBF remain suboptimal (16, 17) .
An alternative approach to that of Saranathan et al is to acquire HSR and HTR images in an interleaved manner. The use of a dual-echo multislice acquisition by Grovik et al (23) hampered measurement of the AIF, but enabled DCE-MRI at HTR while retaining HSR images for clinical use. The purpose of this study is to evaluate the feasibility of quantifying TBF in patients with advanced breast cancer undergoing NACT, using an interleaved DCE-MR imaging technique.
METHODS

Tracer Kinetic Model and Sampling Requirements
A two-compartment exchange model (2CXM) describes the transport of contrast agent through a tumor in terms of TBF (F b ), capillary permeability surface-area product (PS), blood volume fraction (v b ), and extracellular extravascular space (EES) volume fraction (v e ). The following time-domain solution was used for analysis of the signaltime data:
where C p (t) is the AIF, the blood plasma concentration of contrast agent, C(t) is the concentration in the tumor, and is the convolution symbol (15, 24) . The fit parameters (F b , A, a, and b) can be used to derive the required tracer kinetic parameters as follows:
where Hct is the large vessel hematocrit, E is the extraction fraction, and K trans is the volume transfer constant. Quantitative analysis requires a signal from the tumor and the lumen of a feeding artery (the AIF). The proposed interleaved imaging scheme ( Fig. 1 ) starts by acquiring a HSR volume that serves as a baseline reference for clinical reporting. During contrast agent administration, the acquisition scheme continues with HTR sampling to capture the rapid changes of the AIF and tissue curve during the early bolus passes. The acquisition then alternates between HSR and HTR for a further 6 min.
Simulations
To evaluate the performance of the interleaved strategy, a simulation study was undertaken. A realistic AIF (25) was simulated at HTR (0.1 s) and convolved with the tissue model given in Equation [1] (using model and acquisition parameters presented in Table 1 ) to generate three typical tumor curve types: 3, 4, and 5 (26) .
The HTR relative signal intensity (RSI) time curves generated were regridded to match the temporal resolution of our proposed MR technique (2.2 s). Tumor curves and the AIF were further processed to include random Gaussian noise at four different signal-to-noise ratios (SNRs) of 20, 30, 50, and 80. The SNR was defined as the maximum signal intensity in the time series divided by the standard deviation of the baseline signal (27, 28) . A total of 1000 tissue curves were generated for each of the tumor curve types at each SNR level.
The time series were cropped to simulate three sampling strategies ( Fig. 1 
Patients
Eighteen female patients (mean age, 48.7 years) who had locally advanced breast cancer, due to undergo NACT and referred for an MRI scan for treatment assessment, were eligible for this prospective study and were imaged at least twice during their course of NACT. The study was approved by a research ethics committee and written informed consent was obtained. Blood samples from each patient were used to estimate the large-vessel Hct before each MRI scan. Patients with contraindications to MRI were excluded from the study. Table 2 lists the histological and molecular markers acquired from core sample biopsies obtained at baseline and the subsequent NACT regimen for each patient.
MR Imaging
All patients were scanned on a 1.5 Tesla (T) Avanto MR scanner (Siemens, Erlangen, Germany), positioned prone and head first, using a bilateral breast coil for signal reception. To enhance the signal from the descending aorta (which was used for the AIF (14) , as there is no local artery of sufficient diameter that can be reliably measured in the imaging volume), a flexible matrix coil was also positioned on the patient's back.
The clinical protocol began with a T 1 -weighted 3D spoiled gradient echo (FLASH) and a T 2 -weighted turbo spin echo (TSE) sequence, each in the transverse plane covering both breasts. Following this, axial images (field of view 340 Â 340 Â 150 mm, reconstruction matrix 128 Â 128 Â 30) were acquired using a 3D inversion recovery-prepared balanced steady-state free-precession sequence (TrueFISP) at four inversion times (400, 680, 1200, and 2000 ms) to measure the baseline T 1 relaxation times of blood and tumor (inversion-recovery repetition time (TR): 3000 ms; TR/echo time (TE): 2.7/1.3 ms; flip angle (FA): 70 ; GRAPPA parallel factor: 2; T acq : 1 min/volume).
For HTR and HSR DCE-MRI, standard vendor-supplied 3D FLASH sequences were used. No modification was made to the HSR DCE-MRI images used in our institution for clinical reporting. These were preset to run in an interleaved manner as illustrated in Figure 1 . The system was set up to traverse through the sequences in an automated mode, without reshimming or retuning the procedures in between. For the HTR imaging, the same geometry as the T 1 mapping was used (TR/TE: 2.7/0.8 ms; FA: 21 ; GRAPPA factor 2; T acq ¼ 2.2 s). For the HSR images, a 3D fat-suppressed FLASH sequence was used to generate axial images (TR/TE: 4.1/1.2 ms; FA: 10 ; field of view 340 Â 340 Â 146 mm; reconstruction matrix size: 384 Â 384 Â 104; GRAPPA factor: 2; T acq ¼ 34 s). A dose of 0.1 mmol/kg Gd-DOTA (Dotarem, Guerbet Laboratories, Aulnays Sous Bois, France) was administered at 3 mL/s followed by 20-mL saline at the start of HTR imaging. The total acquisition time of the dynamic data was approximately 8 min, during which 84 HTR volumes and 8 HSR volumes were acquired.
Postprocessing
All MRI data were processed using Platform for Research in Medical Imaging, version 0.4 (29) , and MATLAB (MathWorks, Natick, MA). The inversion recovery images were used to obtain baseline T 1,0 relaxation time maps by fitting Equation [2] to the signal intensity data using a nonlinear least-squares optimization algorithm, on a voxel-by-voxel basis:
where S 0 is the steady-state signal. Platform for Medical Imaging was used to draw ROIs in the descending aorta and tumor, to obtain the AIF and the corresponding tumor curve. For AIF selection, ROIs that covered several slices within the 3D volume of HTR data for each patient were first created. The 3D ROIs were then trimmed to include only voxels that had a maximum RSI value between 50 and 95% of all RSI maxima (chosen empirically). A second criterion for AIF selection was that voxels were only included if the corresponding T 1,0 estimates were within 1.1 and 1.7 s. These steps were followed to minimize potential errors in the AIF, such as partial volume, inflow, or motion artifacts. The median number of voxels included in the AIF ROI was 426 (range 105-576). Tumor 3D ROIs were selected on both HSR and HTR images. For the HSR data, a radiologist examined all MRI data sets (T 1 and T 2 -weighted volumes and the postcontrast dynamic data) and delineated the tumor. Both enhancing and nonenhancing areas within the tumor were selected, and these ROIs were used for tumor volume estimation. The 3D ROIs for the HTR images only included regions that exhibited contrast enhancement.
The RSI data were converted to longitudinal relaxation rate changes (DR 1 ) using the mean precontrast T 1,0 estimate and the signal intensity obtained with a FLASH sequence as follows:
where S 0 is proportional to the proton density, and given the short TE used, the term expðÀTE=T Ã 2 Þ was assumed to remain unchanged at a value of 1 throughout. The resulting time series were subsequently used for tracer kinetic modeling. The model was initially fitted with five parameters: the four parameters defined in Equation [1] and the bolus arrival time (BAT) that accounts for the delay between arrival of the contrast at the aorta and the tumor. A second fit was performed with BAT fixed at its best-fit value. The analysis was performed in MATLAB using a constrained nonlinear least-squares optimization algorithm (F b , A, a, and b were constrained to be positive and A < 1). To fill the gaps in the AIF left by the acquisition of HSR data, interpolation was achieved using a bestfit decaying bi-exponential function (30) . The analysis was performed blinded to any clinical results.
To compare T 1,0 , tumor volume and tracer kinetic parameter estimates before and following treatment (for paired data only, n ¼ 10), a nonparametric Wilcoxon signed-rank test was used, as the parameter estimates were not normally distributed (Shapiro-Wilk test, P > 0.05). In addition, Spearman's rank correlation coefficient was used to assess the relationship between parameters (for paired data only). For the analysis of the simulated data, percentage error was calculated for each parameter as follows:
where x and x true are the estimated and the simulated value of the parameter. 
Ductal NST, ductal carcinoma of no specific type; ER, estrogen receptor; PR, progesterone receptor; HER 2, human epidermal growth factor receptor 2; EC, epirubicin and cyclophosphamide; DC, docetaxel and cisplatin; FEC, fluorouracil and EC.
RESULTS
Simulations
Simulated data for all three curve types at four SNR levels were fitted, and parameter estimates were generated. Because of the large quantity of data generated in the simulations (three curve types, four SNR levels, and four estimated parameters per fit), we present only the results for a SNR of 50 (Fig. 2) , which is closest to the mean SNR calculated from the subsequent MRI experiments. The most reliable parameter estimate was F b . Figure 2 demonstrates that all three sampling strategies generate similar median estimates for F b . However, the interquartile range (IQR) in F b estimates was narrowest for method 1, wider for method 2, and widest for method 3. Furthermore, the IQR of F b estimates for all sampling strategies became larger as the curve type changed from type 3 to type 5. Similar effects were observed for both PS and v b estimates. In contrast, v e estimates showed a larger IQR for type 3 and 5 curves compared with type 4. The results for the remaining SNR levels followed similar trends, but the IQR of the parameter estimates increased as the SNR decreased.
Scatter plots for combinations of parameter estimates (Figs. 3 and 4) illustrate that some fit errors occurred with type 3 and 5 curves. In general, these failures become more frequent as the SNR decreased and as the number of data points used to fit the data decreased. Figure 3 demonstrates the low precision in v e estimates for type 3 curves at a SNR of 20, and how this improved at a SNR of 50 and as more data points were used in the fitting process (ie, methods 1 and 2 outperform method 3). Figure 4 (bottom row) shows that fitting a type 5 curve acquired with sampling method 3 and, to a lesser extent, with method 2, leads to fit failures. In particular, 2 and 27% of the fits generate a PS estimate close to 0 for methods 2 and method 3, respectively, and the number of fit failures increased as the SNR decreased. The inability to estimate PS from these data leads to arbitrary v e estimates, an overestimation of v b , and an underestimation of F b . The corresponding scatter plots for type 4 curves (Fig. 4, top row) indicate that the distribution of the parameter estimates is more homogeneous, without fit errors, and with the parameter estimates confined to a narrower range.
Clinical Application
In this cross-sectional feasibility study we analyzed 25 MRI data sets from 15 of the 18 patients recruited; those 15 had baseline MRI scans and 10 of them went on to have MRI scans following two cycles of epirubicin and cyclophosphamide. Three patients missed their baseline scan because of a lack of scanner availability at the time and were excluded from the study. Five patients missed their post-cycle 2 MRI scan because of technical failures or variations in oncology requests for MRI. At surgery following the completion of NACT, 3 of these 10 patients (patients 1, 3, and 14) showed a complete pathological response, and 7 showed evidence of partial pathological response.
Examples of the acquired HSR and HTR images are shown in Figures 5 and 6 , along with the corresponding signal-time curves. Example model fits for patients at baseline and post-cycle 2 are illustrated in Figure 7 . Median values and ranges of the resulting parameter estimates are given in Table 3 . There was a significant change between baseline and post-cycle 2 in F b , BAT, and K trans estimates at the 95% confidence level (P ¼ 0.002, 0.020 and 0.037, respectively). There were no significant changes in the remaining parameters. Tumor volume, determined from the HSR data, decreased by 53% following two cycles of NACT, but this change was not significant at the 95% confidence level (P ¼ 0.065). (14); data not shown), it correlates strongly with F b (q ¼ 0.94, P < 0.001), weakly with PS (q ¼ 0.47, P ¼ 0.037), and shows a more significant reduction following NACT (32%, P ¼ 0.010).
DISCUSSION
In this study, we evaluated the performance of the interleaved acquisition strategy introduced in Figure 1 . The protocol was compared with a conventional HTR protocol in the absence of interleaving through simulations, and clinical feasibility was subsequently tested through application in patients undergoing NACT.
Simulations
The performance of the proposed interleaved strategy (sampling method 2) was comparable to method 1 (HTR without gaps). The IQR of the parameter estimates varied with curve type but improved as SNR increased. F b was the parameter that could be estimated with the highest accuracy and precision, regardless of curve type or SNR.
Simulations using sampling method 1 revealed the sources of error expected when a continuous HTR series is acquired. For type 3 curves, all parameter estimates (except v e ) are confined to a narrow range. When PS is low (type 3), there is slow contrast agent extravasation and the curve continues to rise. The overall acquisition time is suboptimal for this curve type, with insufficient time for the contrast agent to fill the EES. This leads to difficulties in estimating v e , and an uptake model may be more appropriate (15) . Nevertheless, the accuracy and precision of v e estimates improves as SNR increases (Fig. 3) .
The performance of the proposed interleaved acquisition strategy (method 2) was comparable to method 1 in most cases. Similar characteristics were observed for type 3 curves, but v e estimates were more variable. The main difference between the two methods was observed in fitting type 5 curves. Here, extravasation (PS) is high, which makes it difficult to differentiate the contrast agent in the vascular and EES compartments. This may lead to imprecise PS, v e , and v b estimates, worsening as the SNR and number of points used to sample the time series decrease. In the limit PS!1, the model collapses to a one-compartment model, in which the estimate of blood plasma volume fraction (v p ) is equal to v e þ v p , and v e no longer has an effect on the curve and can take any value as seen in approximately 2% of the fits at an SNR of 50. The number of fit errors reduces as the SNR increases. Sampling method 3 was evaluated through simulations to examine the importance of acquiring all rapid temporal changes of the AIF during the first minutes of dynamic acquisition. The results of the simulation suggest that reducing the number of data points can have a significant effect on the parameter estimates. Method 3 generated a higher number of imprecise v e estimates in the case of type 3 curves. Moreover, the percentage of fits that result in fit failure in type 5 curves was appreciably higher (27% of fits for an SNR of 50, increasing as the SNR decreases).
Based on the simulations, we concluded that the proposed interleaved acquisition scheme was able to generate sufficiently reliable parameter estimates compared with those obtained with a conventional HTR protocol. It appears to be important to sample all of the early signal changes in the AIF.
Clinical Application
The acquisition technique proposed offers the potential to derive separate estimates for TBF and PS, and at the same time maintain the acquisition of HSR data necessary for clinical reporting. Because the basic structure of the routine protocol was maintained (other than a delayed acquisition of the first postcontrast HSR volume), our radiologists were able to follow the normal breast MRI reporting system (31) . Figures 5 and 6 show examples of type 5 and type 4 curves with data from the HSR images that match the kinetic curve type derived from the HTR images.
Our estimates of baseline tumor and blood T 1 using the inversion recovery sequence are in the range of previous results (19, (32) (33) (34) . To our knowledge, only Brix et al previously provided F b estimates for breast tumors using DCE-MRI techniques, and these compare well with our F b estimates for untreated tumors (regional blood flow: $0.61 6 0.25 mL/min/mL (14) ). There is also good agreement between v b estimates (0.25 6 0.10), whereas v e reported by Brix (0.34 6 0.16) is somewhat higher than our median estimate. In other studies using PET and O-15 labeled water, whole tumor mean F b estimates in breast tumors range from 30 to 60 mL/min/100 g (8, (35) (36) (37) , but may be systematically underestimated because of limitations in spatio-temporal resolution.
We measured a significant reduction (47%, P ¼ 0.002) in median F b following two cycles of NACT (n ¼ 10). A similar reduction following NACT was also reported using PET imaging by Mankoff et al (7) . K trans has been used in previous MRI studies to monitor treatment response, but this parameter is often measured in different ways and misinterpreted (38) . The physiological interpretation of K trans reflects a combination of TBF and PS (15) . However, the contribution of each process, and hence the sensitivity of the analysis, is likely to be dependent on the model selection. These findings, in conjunction with our simulations, suggest that F b is a good choice for measuring treatment-induced changes.
Limitations
Although 18 patients were initially recruited, only 10 had both baseline and post-cycle 2 MRI scans. Within the study cohort, patients were treated with a variety of NACT regimens, and this complicates any attempt to derive a correlation between TBF change and pathological response.
Although the first segment of HTR data was prolonged to capture the rapid temporal changes in the blood concentration of contrast agent during the first minutes following administration, there were examples of AIF time series with visible first, second, and third passes before the acquisition switched. This should have a minimal effect on F b estimates, but may, in some cases, have an effect on PS and v b estimates. Furthermore, a better sampling strategy for the HTR images could further improve the accuracy and precision of parameter estimates in general. Additional simulations (data not shown) demonstrated that more frequent but shorter sampling intervals could improve these metrics.
It is important to note that a 2CXM is a gross simplification of the true distribution of contrast media in breast cancers. For example, a study has shown that contrast media accumulate within the ducts, 2 min after contrast administration (39) . Nevertheless, the application of complex models is not always the best approach, as this depends on several requirements such as noise in the time series, temporal sampling rate, and accuracy of AIF measurement (40) . In this study, the data did not support a model with more than four parameters.
CONCLUSIONS
To our knowledge, this is the first study that presents an acquisition strategy to acquire both HSR images for clinical reporting and HTR images for quantitative DCE-MRI, with the ability to derive separate estimates of TBF and PS. The interleaved approach was evaluated using simulation studies and tested through application in patients undergoing NACT. These techniques will allow radiologists to adapt similar protocol strategies without significantly compromising the data used for clinical reporting, and encourage other investigators to examine the physiological characteristics of tumors and their associated changes during treatment.
